Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma

British Journal of Haematology

Volumn 158, Issue 2, 2012, Pages 290-292

  Gerecitano, John ^a,b   Gounder, Sivaraman ^c   Teruya Feldstein, Julie ^a   Arcila, Maria ^a   Ogilvie, Shahiba ^a   Gonzalez, Camille ^a   Lin, Dorothy ^a,b   Zheng, Junting ^a   Zhang, Zhigang ^a   McDonald, Alice ^d   Mulligan, George ^d   O'Connor, Owen A ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UCLA MEDICAL CENTER   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bortezomib; CDKN1B; CFLAR; MCL1; Non Hodgkin lymphoma; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; BORTEZOMIB; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLICE INHIBITORY PROTEIN; INTERFERON REGULATORY FACTOR 4; KI 67 ANTIGEN; NY ESO 1 ANTIGEN; PROTEASOME; PROTEASOME SUBUNIT ALPHA5; PROTEASOME SUBUNIT BETA1; PROTEIN BCL 2; PROTEIN BCL 6; PROTEIN MCL 1; PROTEIN P53; SURVIVIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; CANCER PROGNOSIS; CANCER RELAPSE; CANCER SURVIVAL; CARCINOGENESIS; DOWN REGULATION; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE MICROARRAY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; BORONIC ACIDS; HUMANS; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; NEOPLASM PROTEINS; PROTEIN ARRAY ANALYSIS; PYRAZINES; RECURRENCE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84863469158     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09137.x     Document Type: Letter

References (10)

1. Cerchietti, L., Lopes, E., Yang, S., Hatzi, K., Bunting, K., Tsikitas, L., Mallik, A., Robles, A., Walling, J., Varticovski, L., Shaknovich, R., Bhalla, K., Chiosis, G. & Melnick, A. (2009) A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature Medicine, 15, 1369-1376.
2. Chiarle, R., Budel, L.M., Skolnik, J., Frizzera, G., Chilosi, M., Corato, A., Pizzolo, G., Magidson, J., Montagnoli, A., Pagano, M., Maes, B., De Wolf-Peeters, C. & Inghirami, G. (2000) Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood, 95, 619-626.
3. Gerecitano, J., Portlock, C., Moskowitz, C., Hamlin, P., Straus, D., Zelenetz, A.D., Zhang, Z., Dumitrescu, O., Sarasohn, D., Lin, D., Pappanicholaou, J., Cortelli, B.M., Neylon, E., Hamelers, R., Wright, J. & O'Connor, O.A. (2009) Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma. British Journal of Haematology, 146, 652-655.
4. Goy, A., Bernstein, S.H., Mcdonald, A., Pickard, M.D., Shi, H., Fleming, M.D., Bryant, B., Trepicchio, W., Fisher, R.I., Boral, A.L. & Mulligan, G. (2010) Potential biomarkers of bortezomib activity in mantle cell lymphoma from the phase 2 PINNACLE trial. Leukemia & Lymphoma, 51, 1269-1277.
5. Koreishi, A.F., Saenz, A.J., Persky, D.O., Cui, H., Moskowitz, A., Moskowitz, C.H. & Teruya-Feldstein, J. (2010) The role of cytotoxic and regulatory T cells in relapsed/refractory Hodgkin lymphoma. Applied Immunohistochemistry & Molecular Morphology, 18, 206-211.
6. O'Connor, O.A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, O., Qin, J., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. & Zelenetz, A. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 23, 676-684.
7. O'Connor, O.A., Portlock, C., Moskowitz, C., Hamlin, P., Straus, D., Gerecitano, J., Gonen, M., Dumitrescu, O., Sarasohn, D., Butos, J., Neylon, E., Mac-Gregor Cortelli, B., Blumel, S., Evens, A.M., Zelenetz, A.D., Wright, J., Cooper, B., Winter, J. & Vose, J. (2010) Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes. Clinical Cancer Research, 16, 719-726.
8. Paoluzzi, L., Gonen, M., Bhagat, G., Furman, R.R., Gardner, J.R., Scotto, L., Gueorguiev, V.D., Heaney, M.L., Manova, K. & O'Connor, O.A. (2008) The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 112, 2906-2916.
9. Ri, M., Iida, S., Ishida, T., Ito, A., Yano, H., Inagaki, A., Ding, J., Kusumoto, S., Komatsu, H., Utsunomiya, A. & Ueda, R. (2008) Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1. Cancer Science, 100, 341-348.
10. Valnet-Rabier, M.B., Challier, B., Thiebault, S., Angonin, R., Margueritte, G., Mougin, C., Kantelip, B., Deconinck, E., Cahn, J.Y. & Fest, T. (2005) c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome. British Journal of Haematology, 128, 767-773.